Skip to content
PharmaManufacturingIQ

Q&A: Artiva allogeneic NK cell therapies for treating autoimmune disease

After Artiva Biotherapeutics announced the news of cryopreserved allogeneic NK cell therapies (AlloNK) for treating autoimmune disease, European Pharmaceutical Manufacturer spoke to Fred Aslan, president and CEO to learn more.

By PharmaManufacturing IQ Staff
Q&A: Artiva allogeneic NK cell therapies for treating autoimmune disease
Published: | 4 min read
Share to X Share to Bluesky Share to Facebook Share to LinkedIn Share by email

After Artiva Biotherapeutics announced the news of cryopreserved allogeneic NK cell therapies (AlloNK) for treating autoimmune disease, European Pharmaceutical Manufacturer spoke to Fred Aslan, M.D., president and chief executive officer, Artiva Biotherapeutics, to learn more.

Maks_lab Shutterstock

Sign up to our newsletter

The week's biggest stories from this industry, direct to your inbox.

Personal information